# Intranasal CBD Nanocarriers for Dravet and Lennox-Gastaut Syndromes, Promise Before Proof > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-intranasal-cbd-nanocarriers-for-dra-2026-09-20/ > **Published:** 2026-09-20T21:46:52-04:00 | **Last Modified / Clinically Audited:** 2026-10-01T12:33:19-04:00 > **Clinical Summary:** medical cannabis research: Physician review of Nanostructured lipid carriers for intranasal cannabidiol delivery in Dravet and Lennox-Gastaut syndromes: brid... --- CED Clinical Relevance #88 Verified Clinical Evidence Primary literature analysis of Nanostructured lipid carriers for intranasal cannabidiol delivery in Dravet and Lennox-Gastaut syndromes: bridging preclinical promise to clinical translation. Clinical Insight | CED Clinic This review addresses a real clinical problem: oral pharmaceutical CBD can reduce seizures in Dravet syndrome and Lennox-Gastaut syndrome, yet it is limited by delayed absorption, variable bioavailability, liver enzyme effects, gastrointestinal adverse events, somnolence, and meaningful drug interactions, especially with clobazam and valproate. Intranasal nanostructured lipid carriers are biologically plausible because the nasal route may bypass some first-pass metabolism and increase central nervous system exposure. The clinically important point is restraint: the paper does not show that nasal CBD works in children with Dravet syndrome or Lennox-Gastaut syndrome. It proposes a development pathway, supported by animal pharmacokinetic and seizure-model data. Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts. Primary TopicClinical study review: Intranasal CBD Nanocarriers for Dravet and Lennox-. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42751849/) A 2026 review argues that intranasal nanostructured lipid CBD could improve brain delivery for severe childhood epilepsies, but the clinical evidence remains preclinical and translational. What This Study Teaches Us This review searched PubMed, Scopus, Web of Science, and Google Scholar through March 2026 and found no pediatric Dravet syndrome or Lennox-Gastaut syndrome clinical trial proving intranasal NLC-CBD efficacy. The evidence summarized is mainly preclinical, with animal models showing increased brain CBD exposure, higher brain-to-plasma ratios, longer central exposure at lower doses, and anticonvulsant effects in models such as pentylenetetrazol-induced seizures. Why This Matters For patient care, the paper highlights why delivery route matters: CBD’s clinical value can be constrained by slow oral absorption, systemic adverse effects, and drug interactions. For harm reduction, it reminds clinicians not to confuse improved animal brain delivery with proven seizure reduction, safety, or dosing guidance in children. Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceTherapeutic deliveryPublication Date2026Sep17Evidence LevelJournal Article, ReviewFocus AreaIntranasal CBD Nanocarriers for Dravet and Lennox-Gastaut SyLead AuthorsYashika, Sachin Yadav, Anish Arora, Nisha Bharti et al.DOI10.1080/20415990.2026.2731738PMIDPMID: 42751849 Clinical Bottom Line This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** A CBD nose spray could soon deliver fast seizure control for children with Dravet syndrome and Lennox-Gastaut syndrome. **Primary Journal Data:** The article is a narrative translational review, not a pediatric clinical trial. It summarizes preclinical studies of nanostructured lipid carrier CBD showing improved brain exposure, higher brain-to-plasma distribution, and anticonvulsant activity in animal seizure models such as pentylenetetrazol-induced convulsions. It reports no enrolled Dravet or Lennox-Gastaut patients, no randomized pediatric efficacy endpoint, and no long-term pediatric nasal safety dataset. **Dr. Caplan’s Clinical Verdict:** The concept is scientifically credible and worth formal testing, but it is not ready for clinical substitution of approved oral CBD or standard antiseizure regimens. Families should hear this as a promising delivery hypothesis, not as an available, proven treatment. Primary Analysis | Nanostructured lipid carriers for intran **Study Overview:** Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are severe developmental epileptic encephalopathies that appear in early childhood, are unresponsive to medications, and have a dismal neurodevelopmental prognosis. Most patients do not respond well to polytherapy, and the need to fulfill this gap in clinical practice is urgent. Cannabidiol (CBD) has proven to be an effective adjunct drug, but oral preparations have low bioavailability, slow onset and systemic adverse effects. Nanostructured lipid carriers (NLCs) are an innovative therapeutic technology that can deliver CBD directly to the brain via the nose, enhance brain targeting, achieve faster onset, and minimize systemic exposure, which could be a valuable solution to current deficiencies in treatment. Intranasal NLC-CBD has preclinical evidence of increasing brain CBD levels, facilitating anticonvulsant action, and protecting against seizures in established animal models, like pentylenetetrazol-induced convulsions. NLC-based preparations have increased brain-to-plasma ratios and longer central exposure at lower doses in comparison to free or orally administered CBD. Despite these promising findings, there are still translational gaps to be addressed, such as insufficient safety data in the long term, disease-specific DS/LGS genetic models, inconsistencies in the pediatric nasal physiology, and conventional clinical dosing paradigms. Literature for this review was identified through searches of PubMed, Scopus, Web of Science, and Google Scholar, covering studies published up to March 2026 on CBD, NLC, intranasal drug delivery, DS, and LGS.There is a dire need to carry out properly designed clinical trials that would demonstrate the safety, pharmacokinetics (PK) and efficacy of intranasal NLC-CBD in DS and LGS. The first pediatric clinical trials, adaptive trial models and regulatory harmonization are necessary to convert this noble nanomedicine approach into a clinical therapy. Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare and severe forms of epilepsy which often start in childhood. A significant number of patients fail to respond to several antiseizure drugs, and have recurrent seizures. Cannabidiol (CBD) is a chemical found in the cannabis plant that is effective in reducing seizures, but there are some limitations in oral CBD products, including slow absorption and inconsistent efficacy and the possibility for drug interaction. In this review, a novel delivery system of delivering CBD to the brain via a nose spray containing nanostructured lipid carriers (NLCs) is investigated. The use of these tiny lipid-based particles can aid in the delivery of CBD to the brain more rapidly and effectively, avoiding the digestion process and lowering first-pass metabolism. Consequently, intranasal NLC-CBD is likely to have a quicker onset of effect, better brain penetration, and reduced doses. This review provides a summary of existing preclinical evidence, as well as safety and regulatory considerations and outlines the possible clinical development options for this technology. It also underscores some of the future possibilities, such as the application of artificial intelligence (AI), novel clinical trial designs, and combination therapies. While additional clinical trials are necessary, intranasal NLC-CBD is a promising approach for better seizure control, quality of life and treatment ease for DS and LGS patients and their caregivers. **Primary Source & Scope:** Published in *Therapeutic delivery* (2026Sep17) conducted by Yashika, Sachin Yadav, Anish Arora, Nisha Bharti et al. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42751849/) | **Primary Record:** DOI: 10.1080/20415990.2026.2731738 | PMID: 42751849 How Strong Is This Evidence? The evidence strength is hypothesis-generating rather than practice-changing. The paper is a narrative review across multiple databases, which is useful for synthesis, but it does not provide a pooled meta-analysis, enrolled patient sample, randomized clinical comparison, or validated pediatric clinical endpoint. Its strongest data appear to be pharmacokinetic and anticonvulsant findings from preclinical models, which support feasibility but not clinical efficacy. Where This Paper Deserves Skepticism The main limitation is translational distance: pentylenetetrazol and other animal seizure models do not capture the genetic, developmental, and polypharmacy complexity of Dravet syndrome and Lennox-Gastaut syndrome. Intranasal delivery in children is also affected by age, nasal anatomy, mucosal disease, crying, technique, formulation viscosity, device design, and caregiver administration. Publication bias may also favor positive nanocarrier studies while underrepresenting failed formulations, irritation, instability, or inconsistent drug deposition. What This Paper Does Not Show This review does not prove that intranasal NLC-CBD reduces seizures, improves development, or improves quality of life in children with Dravet syndrome or Lennox-Gastaut syndrome. It also does not establish a pediatric dose, regulatory approval pathway, long-term safety profile, or interchangeability with approved oral pharmaceutical CBD. How This Fits With the Broader Clinical Conversation Clinical research into Nanostructured lipid carriers for intranasal canna is progressing through rigorously documented peer-reviewed cohorts. Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries. Dr. Caplan’s Take *This paper is clinically interesting because it focuses on a problem that epilepsy clinicians and families recognize immediately. Oral cannabidiol can be helpful in Dravet syndrome and Lennox-Gastaut syndrome, but its pharmacology is not elegant: variable absorption, food effects, hepatic metabolism, and interactions can complicate care in children already taking multiple antiseizure medications. A nasal lipid nanoparticle formulation that improves brain targeting and reduces systemic exposure would be a meaningful advance if it can be made reproducible, tolerable, and clinically effective.* *The caution is equally important. Dravet and Lennox-Gastaut syndromes are not generic seizure disorders, and animal convulsion models cannot substitute for disease-specific pediatric trials. Before this technology can influence practice, it needs stepwise evidence: formulation stability, nasal mucosal safety, pediatric pharmacokinetics, interaction studies, and randomized seizure outcomes using accepted endpoints such as convulsive seizure frequency or drop seizure frequency. For now, it is a rational research direction, not a prescribing roadmap.* What a Careful Reader Should Take Away Intranasal NLC-CBD is a promising formulation strategy with encouraging preclinical pharmacology, but families should not treat it as a proven therapy. The right next step is carefully designed pediatric clinical research, not off-label experimentation with unvalidated nasal CBD products. Evidence Interpretation Guide Table of Contents - [How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Interpret This Clinical Study Navigating biomedical publications regarding Nanostructured lipid carriers for intranasal requires reviewing study methodology and patient eligibility. ### Three Rules for Critical Reading **Separate delivery data from disease efficacy**improved CBD brain exposure in animals does not prove fewer seizures in children with Dravet syndrome or Lennox-Gastaut syndrome. **Check whether endpoints are clinical or surrogate**pharmacokinetics, brain-to-plasma ratios, and seizure-model protection are useful but not substitutes for pediatric seizure-frequency outcomes. **Look for formulation specificity**one NLC-CBD preparation cannot be generalized to all nasal CBD sprays, lipid nanoparticles, compounded products, or commercial cannabinoid formulations. Key Evaluation Question Does the evidence include controlled pediatric seizure outcomes for the exact intranasal NLC-CBD formulation being proposed? The Patient Question Should my child stay with approved, monitored treatments while we watch for legitimate clinical trials of intranasal CBD delivery? The Bottom Line Intranasal NLC-CBD is a biologically plausible and potentially valuable research direction, but current evidence supports further trials rather than clinical adoption. CED Perspective Lens ## CED Perspective Lens: Eight Clinical Viewpoints Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care. #### Clinical Evidence Synthesis This article is best read as a translational review, not as a clinical efficacy paper. It gathers evidence that nanostructured lipid carriers may improve CBD movement into the brain after intranasal delivery. The most clinically relevant evidence remains indirect: animal pharmacokinetics, seizure models, and formulation studies. There are no reported pediatric Dravet or Lennox-Gastaut randomized outcomes showing fewer seizures with intranasal NLC-CBD. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayPromising delivery biology is not the same as proven pediatric seizure control. #### Patient Communication Families facing Dravet syndrome or Lennox-Gastaut syndrome often live with urgent therapeutic need. A nasal CBD formulation sounds appealing because it suggests faster action and fewer systemic effects. Clinicians should explain that the concept is still investigational. Approved oral CBD has human trial evidence, while intranasal NLC-CBD currently has mainly preclinical support and no established bedside dosing. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayFamilies deserve hope framed with precision, especially when children are medically fragile. #### Dosing & Formulations The review suggests that NLC technology could allow lower CBD doses by improving central nervous system delivery and reducing systemic exposure. That is plausible, but not yet quantified for children. Nasal CBD dosing would depend on particle size, lipid composition, spray volume, mucosal contact time, device performance, and pediatric nasal anatomy. None of these variables translate directly from oral CBD dosing. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayNo clinician should convert oral CBD milligrams into nasal NLC-CBD dosing. #### Safety & Side Effect Profile The safety argument is attractive: less systemic exposure might reduce liver enzyme elevations, diarrhea, appetite changes, somnolence, and interaction burden. However, this remains a hypothesis for this formulation. Intranasal use adds its own safety questions, including mucosal irritation, epistaxis, altered smell, local inflammation, excipient toxicity, device contamination, and uncertain long-term effects in growing children. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayA route designed to reduce systemic risk can introduce new local risks. #### Regulatory & Policy Dynamics A pediatric intranasal CBD nanomedicine would likely require rigorous drug-device and formulation review. Regulators would need evidence for manufacturing consistency, stability, nasal safety, pharmacokinetics, and clinical efficacy. Because Dravet syndrome and Lennox-Gastaut syndrome are rare and severe, adaptive trials and orphan-drug pathways may be relevant. Still, urgency does not eliminate the need for controlled pediatric data. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayRegulatory acceleration can help, but it cannot replace pediatric proof. #### Mechanisms & Physiology Intranasal delivery may access the central nervous system through olfactory and trigeminal pathways, while avoiding some gastrointestinal degradation and hepatic first-pass metabolism. NLCs may improve CBD solubility and residence time. For epilepsy, the key question is whether higher brain exposure occurs in the right regions, at the right time, and with sustained anticonvulsant effect. Brain delivery alone is not a clinical endpoint. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayMechanistic plausibility must ultimately connect to fewer seizures and better function. #### Research Limitations The review highlights major gaps: limited long-term safety data, few disease-specific genetic models, and uncertain translation from adult or animal nasal physiology to young children with severe epilepsy. Preclinical seizure protection is useful, but Dravet syndrome and Lennox-Gastaut syndrome involve developmental biology, comorbidities, and complex medication combinations. Those realities can change both efficacy and tolerability. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayThe largest missing evidence is not formulation promise, but pediatric clinical validation. #### Future Outlook The ideal next program would begin with formulation reproducibility, toxicology, and age-appropriate pharmacokinetics before moving into small pediatric safety studies and adaptive seizure-frequency trials. If successful, intranasal NLC-CBD could become a targeted adjunct for selected patients who struggle with oral absorption, interactions, or delayed onset. That future remains possible, but unproven. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayThe pathway forward is exciting only if it remains methodical and transparent. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Intranasal+CBD+Nanocarriers+for+Dravet+and+Lennox-Gastaut+Syndromes%2C+Promise+Before+Proof&url=https%3A%2F%2Fcedclinic.com%2Fced-intranasal-cbd-nanocarriers-for-dra-2026-09-20%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-intranasal-cbd-nanocarriers-for-dra-2026-09-20%2F) [BlueSky](https://bsky.app/intent/compose?text=Intranasal+CBD+Nanocarriers+for+Dravet+and+Lennox-Gastaut+Syndromes%2C+Promise+Before+Proof%20https%3A%2F%2Fcedclinic.com%2Fced-intranasal-cbd-nanocarriers-for-dra-2026-09-20%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Source: Nanostructured lipid carriers for intranasal cannabidiol delivery in Dravet and Lennox-Gastaut syndromes: bridging preclinical promise to clinical translation.](https://pubmed.ncbi.nlm.nih.gov/42751849/) Related Reading at CED ClinicContinue exploring the evidence[CED Clinic Medical Cannabis Education](https://cedclinic.com/about-us/education/) Explore clinical guides, dosing frameworks, and patient resources from Dr. Caplan. [Read Clinical Resources](https://cedclinic.com/about-us/education/)[Understanding Cannabis Dosing and Ratios](https://cedclinic.com/topic-dosage/) A clinical overview of cannabinoid titration and administration methods for patient care. [View Dosing Guide](https://cedclinic.com/topic-dosage/)[Latest Medical Science and Research Reviews](https://cedclinic.com/category/cannabis-science/) Browse CED Clinic’s archive of peer-reviewed study deep dives. [Browse Science Archive](https://cedclinic.com/category/cannabis-science/) ## Frequently Asked Questions Is intranasal NLC-CBD currently proven for Dravet syndrome or Lennox-Gastaut syndrome? No. This review summarizes preclinical and formulation evidence, but it does not report a completed pediatric clinical trial showing seizure reduction in Dravet syndrome or Lennox-Gastaut syndrome. How is this different from approved oral CBD? Approved oral pharmaceutical CBD has randomized clinical trial evidence for these syndromes. Intranasal NLC-CBD is an investigational delivery approach intended to improve brain targeting and reduce systemic exposure, but it lacks clinical outcome proof. Could a nasal CBD product work faster than oral CBD? Possibly, because intranasal delivery may bypass gastrointestinal absorption and some first-pass metabolism. However, faster onset in children with Dravet syndrome or Lennox-Gastaut syndrome has not yet been clinically demonstrated. Does better brain delivery automatically mean better seizure control? No. Higher brain exposure may improve the chance of effect, but seizure control depends on distribution, dose, timing, disease biology, receptor and network effects, tolerability, and medication interactions. Can families use over-the-counter nasal CBD sprays instead? No. Commercial or compounded nasal CBD products are not equivalent to studied nanostructured lipid carrier formulations and may have uncertain concentration, sterility, excipients, absorption, and safety. Would intranasal CBD avoid all drug interactions? Not necessarily. Reduced systemic exposure might lessen some interaction risk, but CBD can still enter the bloodstream and affect hepatic enzymes. Interactions with clobazam, valproate, and other antiseizure drugs would need formal study. What safety issues matter most for children? Key concerns include nasal irritation, bleeding, inflammation, altered smell, dosing variability, device reliability, excipient safety, systemic CBD effects, liver enzyme changes, sedation, and long-term developmental safety. What kind of clinical trial would be needed? A staged program should include pediatric pharmacokinetics, nasal safety, dose finding, interaction studies, and randomized trials measuring accepted endpoints such as convulsive seizures in Dravet syndrome or drop seizures in Lennox-Gastaut syndrome. Could this replace existing antiseizure medications? There is no evidence that intranasal NLC-CBD can replace standard antiseizure therapy. If eventually proven, it would most likely begin as an adjunct treatment in carefully selected patients. What should caregivers ask their neurologist now? Caregivers should ask whether current CBD therapy is optimized, whether side effects or interactions are being monitored, and whether any legitimate clinical trials of intranasal CBD delivery are available. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).